Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT03638297 |
TitlePD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer | Phase
Phase 2
|
Date Added 2018-08-20 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
PD-1 antibody + cox inhibitor |
Tags
MSI-H/ MMRd
|
| NCT ID NCT05759728 |
TitleA Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer | Phase
Phase 1, Phase 2
|
Date Added 2023-03-08 |
Location
Australia
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05768503 |
TitleComparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC | Phase
Phase 3
|
Date Added 2023-03-14 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Control Rx, Experimental drug |
Tags
MSS/ MMRp
|
| NCT ID NCT05770102 |
TitleDETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition | Phase
Phase 2, Phase 3
|
Date Added 2023-03-15 |
Location
United Kingdom
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Atezolizumab |
Tags
MSI-H/ MMRd
|
| NCT ID NCT05771181 |
TitleVitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients | Phase
Phase 2
|
Date Added 2023-03-16 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Fruquintinib, Tislelizumab, Vitamin E |
Tags
MSS/ MMRp
|
| NCT ID NCT05976906 |
TitleUniversal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors | Phase
Phase 1
|
Date Added 2023-08-04 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05438342 |
TitleAn Expanded Clinical Study of Triple Therapy for Refractory Solid Tumors That Failed First-line Treatment for Recurrence and Metastasis | Phase
Not Applicable
|
Date Added 2022-06-29 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs
Chemotherapy，checkpoint immunotherapy, targeted therapy |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05464030 |
TitleAnti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) | Phase
Phase 1
|
Date Added 2022-07-19 |
Location
California, United States
Rhode Island, United States Texas, United States Canada Japan South Korea Spain |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
M9140 |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05479812 |
TitleDose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors | Phase
Phase 1
|
Date Added 2022-07-29 |
Location
Arizona, United States
Florida, United States Georgia, United States Illinois, United States Indiana, United States Minnesota, United States New Jersey, United States New York, United States Oregon, United States Texas, United States |
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs
Pembrolizumab, WTX-124 |
Tags
MSI-H/ MMRd
|
| NCT ID NCT05482516 |
TitleEvaluating Novel Therapies in ctDNA Positive GI Cancers | Phase
Phase 3
|
Date Added 2022-08-01 |
Location
District of Columbia, United States
New Jersey, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Atezolizumab, Bevacizumab, Avastin, Tecentriq |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
